• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Animal & Veterinary

  • Print
  • Share
  • E-mail

NADA 141-071 Imizol® - original approval

Approval Date: November 7, 1997

I. GENERAL INFORMATION:

NADA141-071
Sponsor:Schering-Plough Animal Health
1095 Morris Avenue
Union, New Jersey 07083
Generic Name:imidocarb dipropionate
Trade Name:Imizol®
Marketing Status:Prescription

 

II. INDICATIONS FOR USE

For the treatment of babesiosis in dogs with clinical signs and/or demonstrated Babesia organisms in the blood.

 

III. DOSAGE FORM, FOUTE OF ADMINISTRATION, AND RECOMMEND DOSAGES

IMIZOL® is a 12% solution of imidocarb dipropionate. It contains 120 mg of active imidocarb per milliliter (mL) of solution. It is available in 10 mL rubber stopper vials and is intended for intramuscular or subcutaneous injection. IMIZOL® is to be administered at a rate of 6.6 mg/kg b.w. (3 mg/lb) (i.e. 0.25 mL/10 lb.). Repeat the dose in two weeks for a total of two treatments.

DOSING GUIDE 6.6 mg/kg b.w.

Animal WeightIMIZOL® Dosage (mL)
10 lb. (4.5 kg)0.25 mL
20 lb. (9.1 kg)0.50 mL
30 lb. (13.6 kg)0.75 mL
40 lb. (18.2 kg)1.00 mL
60 lb. (27.3 kg)1.50 mL
80 lb. (36.4 kg)2.00 mL
100 lb. (45.5 kg)2.50 mL

 

IV. EFFECTIVENESS

Dose Selection was based upon the following:

  1. The literature and the field studies support the efficacy of a dose range from 4 to 10 mg/kg subcutaneously(SC) or intramuscularly (IM).
  2. Safety studies have demonstrated safe levels of Imizol up to 9.9 mg/kg.
  3. The dose/dose volume is convenient to calculate based upon the 12% solution (120 mg/mL).

Imidocarb dipropionate has been used throughout the world to treat babesiosis in cattle, sheep, horses and dogs. Imidocarb dipropionate was approved in the United States for treatment of babesiosis in horses (NADA 97-288) on September 12, 1978.

Babesia in dogs is an intra-erythrocytic parasite and can be difficult to diagnose. Several presentations of Babesiosis have been described in dogs. The most common presentation of Babesiosis in the U.S. is the subclinical carrier state. Parasites are rarely seen on blood smears and clinical signs are inapparent unless the dog is stressed or put on corticosteroid therapy. Puppies born to carrier bitches may become clinically ill, with a high mortality rate in untreated puppies. Mortality rates can also be high in immunocompromised adults.1

1 Hoskins, DVM, PhD (Editor). The Veterinary Clinics of North America, Small Animal Practice, Tick Transmitted Disease. January 1991:21(1):103-123.

Techniques for diagnosis of babesiosis include blood smears and detection of antibody titers.

A. Dose Determination

From 1980 through 1984, Imizol® was evaluated in several dose determination studies (Guelfi 1980, 1981; Euzeby 1981; Awaz 1984). Treatment effects of Imizol® (12% w/v aqueous solution) against Babesia canis in dogs (n=93) were assessed at dose rates of 0, 1, 2, 3, 4, 5 or 6 mg/kg b.w. These studies are summarized in Table 1.

  1. Imizol® 1 mg/kg b.w.
    Five (5) dogs with natural infections (n=3; Guelfi 1980) or induced infections (n=2; Euzeby 1981) received 1 mg Imizol®/kg b.w. Two dogs with natural infections recovered, but one relapsed a few days after treatment. The two dogs inoculated with Babesia canis and treated with a single injection of Imizol® at this dose rate were not cleared of the parasites in the blood, Table 1, page 4 of this document.
  2. Imizol® 2 mg/kg b.w.
    Sixty-seven (67) dogs with natural Babesia canis infections (Guelfi 1980) were treated with 2 mg Imizol®/kg b.w. Fifty-nine dogs recovered rapidly. Poor to fair results were reported in 8 dogs (relapsed or not in complete recovery). Two (2) dogs died of babesiosis and 3 dogs were not returned by the owners for evaluation. Rapid recovery was noted in most dogs. Some dogs relapsed within six months post-treatment (Guelfi 1981). Guelfi (1981) recommended a higher dose rate.
  3. Imizol® 3 mg/kg b.w.
    Nine (9) dogs with natural Babesia canis infections were treated (Guelfi 1980; Euzeby 1981). All dogs recovered rapidly and there were no relapses or deaths. No parasitemia developed in any of the dogs one month after treatment. One author reported that there were no relapses at 11 months post-treatment.
  4. Imizol® 4 or 5 mg/kg b.w.
    The treatment effects of Imizol® were assessed in 8 dogs naturally infected with Babesia canis. Three dogs received Imizol® at a dose rate of 4 mg/kg b.w. (Euzeby 1981), and 5 dogs received 5 mg/kg b.w. (Euzeby 1981, Guelfi 1980) by intramuscular or subcutaneous injection. All dogs recovered rapidly and no relapses were reported.
  5. Imizol® 6 mg/kg b.w.
    Nine splenectomized dogs were inoculated with Babesia canis (Awaz 1984). Four dogs received treatment with 6 mg Imizol® /kg b.w. by a single intramuscular injection, 4 dogs received an alternative treatment, and one dog served as an untreated control. In the Imizol® group, 3 dogs recovered in a short time following treatment and 1 dog died. All dogs receiving the alternative treatment recovered. The dog which served as the untreated control died of babesiosis.

Note: Guelfi (1980) tested dose rates of 1, 2, 3 and 5 mg Imizol®/kg b.w. A total of 63 dogs treated with an alternative treatment served as controls for each of the dose rate comparisons.

Table 1. Imizol® (12% imidocarb dipropionate) dose determination for treatment of Babesia canis. Dose was established from the evaluation of 93 dogs treated with Imizol® [Internal Mallinckrodt Reports (Guelfi 1980; Guelfi 1981; Euzeby, 1981) and scientific publications (Awaz 1984)].

ReferenceNo of
Dogs
Type of
Infections
Therapy & DoseRouteRecoveredRelapseDeathsComments
Guelfi 1980a3NaturalImizol®sc210One dog relapsed within a few days of treatment.
Euzeby 19812Inoculate1 mg/kg b.w.im020Dogs received a single treatment within 24 hours of inoculation. Some chemo-immunizing properties were suspected but not definitive. Babesia canis was present in the blood of both dogs.
Guelfi 1980a2NaturalImizol®sc200Rapid recovery. Some parasitemia in young dogs.
Guelfi 1980a65Natural2 mg/kg b.w.sc5732No data was available for 3 dogs. Recovery was rapid in most cases. Fair to poor results were reported for 3 dogs which are categorized here as relapses. Two dogs died of babesiosis. A higher dose was recommended.
Guelfi 1981Follow-up of above cases at six month post-treatment5091Nine dogs apparently recovered then relapses occurred 6 months post-treatment. Some owners did not respond to the follow up. One dog died of babesiosis.
Guelfi 1980a2NaturalImizol®sc200Rapid recovery.
Euzeby 19817Natural3 mg/kg b.w.im700Recovered within 24 hours. No relapses at 11 months
Euzeby 19813NaturalImizol® 4 mg/kg b.w.im300Recovered within 24 hours.
Euzeby 19813NaturalImizol® 5 mg/kg b.w.im300Recovered within 24 hours.
Guelfi 1980a2Natural
 
sc200Rapid recovery.
Awaz 19844InoculateImizol® 6 mg/kg b.w.im301Dogs recovered rapidly and one dog died shortly after treatment.

Dose Determination Literature Cited

K. B. Awaz, et al. Therapeutic Efficacy of Berenil and Imizol® against Experimental Babesia canis infection in Dogs. Indian J of Parasitology. 1984; 8(1): 111-112

B. Dose Confirmation:

A total of 1,031 dogs (10 were controls), from two published reports (Ogunkoya 1981; Bodade 1986) are summarized for dose confirmation, Table 2. Dogs naturally infected with Babesia canis received a 12% w/v aqueous solution of Imizol® (imidocarb dipropionate) dosed at the rates of 5 or 6 mg/kg b.w. administered by a single subcutaneous or intramuscular injection.

Ogunkoya (1981) evaluated the effectiveness of Imizol® when administered at a dose rate of 5 mg/kg b.w. All dogs (n=1,011) received a single subcutaneous injection. Two disease categories are reported here: Group 1 consisted of 808 dogs infected with Babesia canis, and Group 2 included 203 dogs infected with B. canis and concurrently infected with other tick- borne parasites. Treatment with Imizol® resulted in complete recovery of 763 dogs (94.4%) in Group I, and 159 (78.3%) dogs in Group II. At 3 months post-treatment, 25 dogs (0.03%) in Group I relapsed after an apparent recovery. No data was provided as to relapses occurring in Group II. No adverse reactions to Imizol® treatment were reported.

Bodade (1986) evaluated 20 clinically ill pet dogs of various breeds and ages (range 3 months to 7 years). Ten dogs served as untreated controls and 10 dogs received Imizol® at a rate of 6 mg/kg b.w. by intramuscular injection. Antibody titers to B. canis were determined for both treated and untreated dogs on a bi-weekly basis for 12 to 24 weeks after treatment. Eight (8) of the 10 dogs treated with Imizol® recovered and were still normal 6 months post-treatment with negative antibody titers. Two (2) dogs relapsed 10 weeks after treatment. Four (4) of the 10 control dogs developed clinical babesiosis and had to be treated, 2 others exhibited self cures and the remaining 4 dogs had positive titers and were asymptomatic carriers. No adverse reactions to Imizol® treatment were reported.

Table 2. Dose confirmation summary. A total of 1,031 dogs from two published reports (Ogunkoya, 1981; Bodade, 1986) are summarized. All dogs were naturally infected with Babesia canis. Dogs received a single injection of 12% w/v aqueous solution of imidocarb dipropionate dosed at 5 or 6 mg/kg b.w.
ReferenceTreatmentNo of
Dogs
Dose
mg/kg
b.w.
RouteRecoveredRelapseDeathsComments
Ogunkoya 1981Imizol®8085sc763250At 6 weeks post-treatment, 20 dogs had detectable parasitemia but were not clinically ill.
Ogunkoya 1981aImizol®2035sc15900Treatment was reported to be highly effective. No relapse information.
Bodade 1986Imizol®106im1020Two dogs relapsed 10 weeks post-treatment; 8 dogs were normal at 6 months post-treatment and titers declined until not detectable.
Bodade 1986Control1000200All dogs with positive titers but not clinically sick. 4 dogs developed babesiosis and had to be treated, and 6 dogs were considered carriers. Two dogs were self cured.
a Dogs were concurrently infected with B. canis and other hemoparasites.

Dose Confirmation Literature Cited

P. A. Bodade, O. O. Oduye. Antibody titers in naturally occurring Babesia canis infections in dogs. Revue D' Elevage Et De medicine Veterinaire Des pays Tropicaux. 1986; 39(2): 185-188.

A. B. Ogunkoya, J.B. Adeyanju and Y.O. Aliu. Experiences with the use of Imizol® in treating canine blood parasites in Nigeria. J. Small Anim. Pract. 1981; 22: 775-777.

C. Field Trials:

Clinical effectiveness was demonstrated in two published papers (Irwin 1991, Adeyanju 1982) and one clinical trial conducted in the United States. Results from these two papers and the clinical trial are listed in Table 3. The names of the investigators in the clinical trial are listed in Table 4.

Imizol® was administered at doses of 4 - 5 mg/kg b.w. or 10 mg/kg b.w. to 325 pet dogs with natural infections of only Babesia canis or concurrent infections with other hemoparasites (Table 3, page 9). In one paper (Irwin 1991), 8 puppies (4-9 weeks old) served as controls. All eight puppies died of babesiosis. The global distribution of these field cases involves the United States (n=45), Nigeria (n=265), and Australia (n=16 + 8 controls).

Number of DogsTreatment Group
3134-5 mg/kg
imidocarb
1210 mg/kg
imidocarb
124 mg/kg
imidocarb
8controls
total of 334 dogs; 326 treated/8 controls 

Imizol® was administered at a dose rate of 4 to 5 mg/kg b.w. by intramuscular or subcutaneous injection to a total of 313 dogs. Twelve dogs received 10 mg/kg b.w. Complete recovery or a progressive remission of clinical signs was reported in 90% (294/325) of the cases treated with either 4 to 5 mg/kg or 10 mg/kg of imidocarb. Some owners did not follow-up; therefore, treatment results were unknown for sixteen dogs. Six of the 325 dogs never exhibited clinical signs, therefore were not classified as recovered or relapsed. Two of the 5 mg/kg b.w. imidocarb-treated dogs relapsed after initial recovery.

All eight (8) of the untreated puppies died. One (1) dog which received 24 mg/kg b.w. (accidental overdose) died of Imizol® toxicity. Seven (7) dogs died of babesiosis despite administration of imidocarb at 4-5 mg/kg b.w. None of the dogs which received the 10 mg/kg dose died.

Pain at the time of injection and salivation were frequently reported by veterinarians in the United States. Other transient adverse effects reported were nasal drips, vomiting, panting, agitation, and injection site swelling. Two deaths were reported to be treatment related and were discussed previously (See Table 3). Adeyanju (1982) reported that none of the dogs treated exhibited adverse reactions.

Table 3 Field Trial summary. Dogs naturally infected with B. canis alone or concurrently with other tick-borne parasitic diseases were evaluated. Data were obtained from two published papers and one study report (from a U.S. clinical field trial) which demonstrates the effectiveness of Imizol®.

ReferenceNo of
Dogs
Imizol®
Dose Rate
mg/kg b.w.
RouteRecoveredRelapseDeathComments
Irwin 19918Controls0008All were puppies 4-9 weeks old
Irwin 1991165im10No data4Four puppies less than 10 weeks old died of babesiosis; Author did not report on all cases.
Adeyanju 19822605im2490095.8% of the dogs recovered. Progressive remission of clinical signs and improvement in hematological values. Parasites were detected in 10 dogs 6 weeks post-treatment..
Adeyanju 1982a55im30260% recovered. Progressive remission of clinical signs and improvement in hematological values. No parasites in the blood at 6 weeks post-treatment.
Clinical Trial 199614im100Dog received a second treatment 14 days after the first.
Clinical Trial 1996315im, sc2521 aThirteen dogs received two treatments. Twelve dogs with clinical babesiosis returned to normal. Some owners did not return for follow-up. One dog with a concurrent hemoparasite infection never improved and eventually died.
Clinical Trial 19961210im, sc600Six dogs did not exhibit pronounced clinical signs of Babesiosis. One dog had a concurrent infection of another hemoparasite and remained the same. Some owners did not return for follow up evaluations.
Clinical Trial 1996124im001Dog was overdosed and died.
a Dogs were concurrently infected with B. canis and other hemoparasites.

Table 4. List of field trial investigators who contributed to the U.S. clinical field trial:

Steven Bowen, DVM
Valley Veterinary Hospital
485 Broadway, Suite F
El Centro, CA 92243
619-352-1279
Diane Chesebro, DVM
All Animal Clinic
5505 5th Avenue
Key West, FL 33040
305-294-5255
Steven Covert, DVM
Altamonte Veterinary Hospital
1089 E. Altamonte Drive
Altamonte, FL 32701
407-339-1922
Danny Dillon, DVM
Kenersville Veterinary Hospital
209-A Century Park Blvd.
Kenersville, NC 27284
910-996-3748
Robert Doak, DVM
VCA Wyoming Animal Hospital
1300 Wyoming Blvd. N.E.
Albuquerque, NM 87112
505-298-7444
Christine Ellis, DVM
Arborview Animal Hospital
244 W US Hwy 6
Valparaiso, IN 46383
219-762-7267
Janice Fenichel, DVM
ASPCA
424 E. 92nd St.
New York, NY 10128
212-876-7700
Joseph Giangarra, DVM
Mountain Lore Animal Hospital
765 South End Rd.
Southington, CT 06479
860-276-8553
Russell Greene, DVM
Phoenix Veterinary Internal Medicine Services
13633 N. Cave Creek Rd.
Phoenix, AZ 85022
602-788-2400
Darin Hisanaga, DVM
Waipahu Leeward Veterinary Clinic
94-801 Farrington Highway Suite 3
Waipahu, HI 96797
808-671-4095
Gayland Jones, DVM
Wabash Valley Animal Hospital
3004 South 7th St.
Terre Haute, IN 47802
812-232-5414
Suellen Kotake-Hollars, DVM
All Pets Clinic
94-366 Pupupani St.
Waipahu, HI 96797
808-671-8424
Vincent LoDuca, DVM
Aycock Veterinary Clinic
5490 Stirling Rd.
Davie, FL 33314
954-989-8393
William Losch, DVM
St. Paul Veterinary Clinic
2620 W. St. Paul
Milwaukee, WI 53233
414-342-7800
Louise Morgan, DVM
Brewster Veterinary Clinic
56 Underpass Rd.
Brewster, MA 02631
508-896-2540
Kerlin Nogle, DVM
Aerowood Animal Hospital, P.S., Inc.
2975 156th S.E.
Bellevue, WA 98007
206-746-6557
H.J. Rebhan, DVM
Waianae Veterinary Clinic
85-794 Farrington Hwy
Waiamae, HI 96792
808-696-4161
John Robb, DVM
New Fairfield Vet Hospital
36 Route 37
New Fairfield, CT 6812
203-746-3041
G.A. Robertson, DVM
Levy Pet Clinic
4242 W. 47th St.
North Little Rock, AR 72118
501-758-8550
Joanne Woltmon, DVM
Kauai Veterinary Clinic
1864 Haleukana Street
Lihue, HI 96766
808-245-4748

Field Trials Literature Cited

P. J. Irwin, and G. W. Hutchinson. Clinical and pathological findings of babesia infections in dogs. Australian Veterinary J. 1991; Vol. 68(6):204-209.

B. J. Adeyanju, and Y.O. Aliu. Chemotherapy of Canine Ehrlichiosis and Babesiosis with Imidocarb Dipropionate. J of the AAHA;1982 Sept/Oct, Vol 18:827-830

 

V. ANIMAL SAFETY

A. Toxicity Study

Imizol was administered to four groups of ten, 9 month-old Beagle dogs at 2.2, 5.5, 7.7 or 9.9 mg/kg b.w. subcutaneously, given twice with two weeks between doses. A control group (ten similar animals) was administered saline in an identical manner.

Imizol® caused pain on injection in nearly all animals, regardless of dose. One injection site reaction (ulceration of injection site) occurred at the highest dose (9.9 mg/kg). Injection site reactions (swelling) after the second injection of Imizol were present in 4 out of the 10 dogs which received the lowest dose (2.2 mg/kg) and in all of the dogs which received the higher doses of Imizol. The dog that developed the injection site ulceration after the first dose of 9.9 mg/kg Imizol also developed injection site ulceration after the second dose of 9.9 mg/kg Imizol.

Post-treatment vomiting was seen in all Imizol-treated groups at a frequency of 1 to 4 out of 10 dogs. The adverse effect was not dose related nor did the dogs respond the same to both injections. These results are consistent with the cholinergic effects attributed to Imizol.

On Days 21, 28 and 35 of the study there was a statistically significant increase in serum alanine aminotransferase (ALT, SGPT) and arginine aminotransferase (AST, SGOT) in the 9.9 mg/kg b.w. as compared to the placebo group. At Day 42, these differences were no longer apparent.

Imizol® had no effects, at any dose level, on body temperature, body weight, hematology, other clinical chemistry values or gross pathology. This study demonstrates that the margin of safety for Imizol® administered to dogs at 6.6 mg/kg b.w. subcutaneously and repeated in two weeks is adequate for its intended use.

B. Tolerance Study

Imidocarb was given orally to three groups of eight, 14 -16 week-old beagle dogs at the rate of 5, 20, or 80 mg/kg daily for 90 days. A fourth group of similar dogs served as untreated controls.

In the 80 mg/kg group, all the male dogs(4) died during the trial and two of the females were euthanized in extremis. Their clinical signs included salivation, diarrhea, anorexia, dyspnea, tachycardia, listlessness and weakness. Clinical chemistries showed elevations of serum alanine aminotransferase (ALT, SGPT) and arginine aminotransferase (AST, SGOT) in the 80 mg/kg treated animals just prior to their death. Post mortem examinations revealed moderate to advanced fatty infiltration in the livers of all animals in the 80 mg/kg group. Other findings in this group were inflammation, thickening and congestion of the intestine and stomach. Histopathology of those animals that died or were killed in extremis revealed hemorrhagic necrosis of the centrilobular areas of the liver, vacuolation of the hepatocytes in the non-necrotic areas and proliferation of the bile duct epithelium. Fat deposition in Henle's loop and distal convoluted tubules of the kidney was noted. In addition, pyknosis and karyorrhexis of cells in the thymus, spleen, lymph nodes, liver and villi of the small intestine were seen. Histopathologic findings of the two survivors of this group revealed hepatocyte vacuolation and esoinophilic hyaline globules in centrilobular hepatocytes, but no other significant findings.

In the 20 mg/kg group, all animals had moderate to advanced fatty infiltration of the liver. Other findings were inflammation, thickening and congestion of the intestine and stomach. Histopathology revealed three dogs with hepatocyte vacuolation and two dogs with focal hepatitis.

There were no changes of toxicological significance in the 5 mg/kg group as compared to controls.

The target organs of toxicity were liver and intestines in this study of imidocarb using the oral route of administration.

C. Additional Safety Information:

In a pharmacokinetic study conducted by Abdullah et al (1984), imidocarb was given to dogs intravenously at a dose of 4 mg/kg. One of 13 dogs died on post-treatment Day 8. The dog that died had clinical signs characterized by anorexia, listlessness, dypsnea, tachycardia, weakness and profuse diarrhea. The target organs of toxicity in this dog were lungs and kidneys, and some changes were noted in the liver and spleen. Adverse reactions in all thirteen dogs were salivation and diarrhea.

D. Summary of toxicity:

The toxic syndrome involves lethargy, weakness and anorexia, with possible signs of gastrointestinal, liver, kidney and lung dysfunction.

Literature Cited

A. S. Abdullah, et al. Adverse Effects of Imidocarb Dipropionate (Imizol®) in a Dog. Veterinary Research Communications. 1984 (8):55-59

 

VI. HUMAN FOOD SAFETY:

Data on human safety, pertaining to consumption of drug residues in food, were not required for approval of this NADA. The drug is labeled for use in dogs, which are non-food animals.

 

VII. AGENCY CONCLUSIONS:

The data submitted in support of this NADA satisfy with the requirements of Section 512 of the Federal Food, Drug, and Cosmetic Act and Part 514 of the implementing regulations (Title 21 of the Code of Federal Regulations). The data demonstrate that Imizol (imidocarb dipropionate), when used under labeled conditions of use, is safe and effective for the treatment of babesiosis in dogs.
Labeling restricts this drug to use by or on the order of a licensed veterinarian because professional expertise and proper diagnosis are required to determine an infection with Babesia organisms.

FDA has determined under [[section]]25.33 (See 62 FR 40570, 40596, July 29, 1997 to be codified at 21 CFR Part 25) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Under section 512(c)(2)(F)(ii) of the FFDCA, this approval for non-food producing animals qualifies for THREE years of marketing exclusivity beginning on the date of approval because the application contains substantial evidence of the effectiveness of the drug involved, or studies of animal safety required for the approval of the application and conducted or sponsored by the applicant.

 

VIII. LABELING (Attached)

  1. Package insert
  2. Vial
  3. Carton
  4. Display Carton

Copies of applicable labels may be obtained by writing to the:

Freedom of Information Office
Center for Veterinary Medicine, FDA
7500 Standish Place
Rockville, MD 20855